Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Ravulizumab profile to treat PNH and aHUS is equivalent to eculizumab in efficacy and safety but allows extended dosing interval to every 4-8 weeks based on patient weight, and requires reduced infusion time. Less travels to infusion centers and medical visits and decreasing job and school absences significantly increase patient and families' QoL, while reducing cost. Further infusion time is reduced. Ravulizumab will possibly become the treatment of choice for patients with PNH and aHUS on chronic C5 inhibition.